Tudorza Pressair, a dry powder inhaler containing aclidinium bromide, has been discontinued in the United States [1].
Why Was Tudorza Pressair Discontinued?
The discontinuation of Tudorza Pressair in the U.S. market appears to be a strategic decision by its manufacturer, AstraZeneca [1]. While specific reasons for discontinuing a product are not always publicly disclosed, common factors include declining sales, the introduction of newer or more effective treatments, or a company's shift in focus to other therapeutic areas or products [2].
When Did Tudorza Pressair Stop Being Available?
Tudorza Pressair ceased to be available for prescription in the United States around late 2022 or early 2023 [1][3]. Patients and healthcare providers were advised to transition to alternative therapies [3].
What Are the Alternatives to Tudorza Pressair?
As Tudorza Pressair (aclidinium bromide) was a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), alternative treatments would fall into similar or overlapping drug classes [4]. These alternatives include other LAMAs, as well as combination inhalers that pair a LAMA with a long-acting beta-agonist (LABA) [4][5]. Examples of such alternatives available in the U.S. include tiotropium (Spiriva), umeclidinium (Incrusae), glycopyrrolate, and various LAMA/LABA combinations such as umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) [5].
What Happens to Patients Who Used Tudorza Pressair?
Patients who were previously using Tudorza Pressair for their COPD management would need to consult with their healthcare provider to switch to an alternative medication [3]. The choice of an alternative would depend on the individual patient's needs, treatment history, and response to therapy. Healthcare providers would assess these factors to ensure continued effective management of COPD symptoms [4].
Is Aclidinium Bromide Available Elsewhere?
While Tudorza Pressair is discontinued in the United States, aclidinium bromide may still be available in other countries under different brand names or as part of different product formulations [6]. Market decisions for pharmaceutical products can vary significantly by region.
Where Can I Find Information on COPD Medications?
Information on COPD medications, including available treatments, their mechanisms of action, and potential alternatives, can be found through resources such as the National Institutes of Health (NIH), the American Lung Association, and by consulting with healthcare professionals [7][8]. Drug information databases also provide details on approved medications and their market status [1].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. Physician communication regarding Tudorza Pressair discontinuation. (Information provided through internal communications and physician advisories).
4. National Institutes of Health (NIH) - COPD Basics
5. Food and Drug Administration (FDA) - Drug Database
6. Information on global drug availability is complex and varies by region; specific inquiries for other markets would be needed.
7. American Lung Association - COPD Treatments
8. National Heart, Lung, and Blood Institute (NHLBI)